Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Similares en SciELO
Compartir
Gaceta mexicana de oncología
versión On-line ISSN 2565-005Xversión impresa ISSN 1665-9201
Resumen
MEDINA-ORNELAS, Sevastián y GRANADOS-GARCIA, Martín. Thyroid cancer, redefining the radioiodine-refractoriness (RAIR). Gac. mex. oncol. [online]. 2021, vol.20, n.4, pp.148-157. Epub 06-Dic-2021. ISSN 2565-005X. https://doi.org/10.24875/j.gamo.21000058.
Differentiated thyroid cancer (DTC) maybe is the neoplasm with the best outcome; however, the development of metastases means a less favorable scenario, where the use of iodine-131 (I-131) represents the best therapeutic option; although a group of patients will not get a good response. It is important to know the multidisciplinary approach to this condition, since it produces the best results; but it is important to understand the phenomenon of radioiodine-refractoriness (RAIR); since there is currently a lot of controversy. Next are describe 5 categories of the RAIR, these classifications seek to obtain the greatest benefit from treatment with I-131.
Palabras llave : Differentiated thyroid cancer; Radioiodine-refractoriness; Iodine-131.